Recombinant Human Neuroligin 1v2/NLGN1v2 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Neuroligin 1v2/NLGN1v2 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Neuroligin 1/NLGN1 Variant 2 is immobilized at 5.0 μg/mL, Recombinant Human Neurexin 1 beta Fc Chimera (Catalog # 5268‑NX) binds with an apparent K_D < 30 nM.
• Source: Mouse myeloma cell line, NS0-derived human Neuroligin 1/NLGN1 protein
  Met1-Ser677, with a C-terminal 6-His tag
• Accession #: NP_055747
• N-terminal Sequence: No results obtained: Gln46 predicted, sequencing might be blocked
• Protein/Peptide Type: Recombinant Proteins
• Gene: NLGN1
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 71.3 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-110 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 300 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Neuroligin 1v2/NLGN1v2 Protein, CF

• EC 3.1.1
• EC 3.1.1.1
• KIAA1070neuroligin-1
• MGC45115
• Neuroligin 1
• NL1
• Nlg
• NLGN1

Background

Neuroligin 1 (NLGN1 or NL1) is one of several type I transmembrane Neuroligin proteins that play an important role in synaptic development (1). Mature human Neuroligin 1 is an N- and O-glycosylated 120 kDa molecule that consists of a 649 amino acid (aa) extracellular domain (ECD) with a catalytically inactive cholinesterase-like domain, a 21 aa transmembrane segment, and a 125 aa cytoplasmic tail (2). In rat, insertion of 20 aa at splice site A and/or 9 aa at splice site B within the ECD results in NLGN1A, NLGN1B, or NLGN1AB isoforms while the NLGN1(-) isoform has neither insertion (3). This recombinant protein lacks the splice site A insert but contains the splice site B insert and corresponds to the human equivalent of rat NLGN1B. Within the ECD, human NLGN1A shares 99% aa sequence identity with comparable regions of mouse and rat Neuroligin 1, respectively. Neuroligin 1 expression is restricted to postsynaptic nerve terminal membranes where it associates into dimers and tetramers (5 ‑ 7). NLGN1B and NLGN1AB are enriched at excitatory (glutamatergic) contacts, whereas NLGN1A is enriched at inhibitory (GABAergic) contacts and NLGN1(-) is expressed at both (3). The interaction of Neuroligin 1 with presynaptic membrane Neurexins promotes the maturation of presynaptic as well as postsynaptic structures (3, 4, 8 ‑ 11). Neuroligin 1 isoforms are selective in which Neurexin isoforms they bind: NLGN1B and NLGN1AB preferentially interact with Neurexin 1 beta lacking the splice site 4 insert, while NLGN1A and NLGN1(-) bind Neurexin 1 alpha and Neurexin 1 beta irrespective of the SS4 insert (12). Neurexin 1 beta (-SS4) additionally binds to LRRTM2 to trigger a second mechanism that promotes excitatory synapse development (13, 14). Neuroligin 1 mediated synaptogenesis is also enhanced by its direct binding to Thrombospondin 1 (15).

1. Sudhof, T.C. (2008) Nature 455:903.
2. Ichtchenko, K. et al. (1995) Cell 81:435.
3. Chih, B. et al. (2006) Neuron 51:171.
4. Dean, C. et al. (2003) Nat. Neurosci. 7:708.
5. Comoletti, D. et al. (2006) Biochemistry 45:12816.
6. Berninghausen, O. et al. (2007) J. Neurochem. 103:1855.
7. Song, J.-Y. et al. (1999) Proc. Natl. Acad. Sci. 96:1100.
8. Wittenmayer, N. et al. (2009) Proc. Natl. Acad. Sci. 106:13564.
9. Jung, S.-Y. et al. (2010) Proc. Natl. Acad. Sci. 107:4710.
10. Chubykin, A.A. et al. (2007) Neuron 54:919.
11. Chih, B. et al. (2005) Science 307:1324.
12. Boucard, A.A. et al. (2005) Neuron 48:229.
13. Siddiqui, T.J. et al. (2010) J. Neurosci. 30:7495.
14. Ko, J. et al. (2009) Neuron 64:791.
15. Xu, J. et al. (2010) Nat. Neurosci. 13:22.

Publications for Neuroligin 1/NLGN1 (7066-NL)(3)

Publications using 7066-NL

• Voss, AJ;Lanjewar, SN;Sampson, MM;King, A;Hill, EJ;Sing, A;Sojka, C;Bhatia, TN;Spangle, JM;Sloan, SA; Identification of ligand-receptor pairs that drive human astrocyte development Nature neuroscience 2023-07-17 [PMID: 37460808] (Bioassay, Human)
• E Camporesi, T Lashley, J Gobom, J Lantero-Ro, O Hansson, H Zetterberg, K Blennow, B Becker Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers Acta neuropathologica communications, 2021-02-01;9(1):19. 2021-02-01 [PMID: 33522967] (Reference Standard, Human)
• HS Venkatesh, LT Tam, PJ Woo, J Lennon, S Nagaraja, SM Gillespie, J Ni, DY Duveau, PJ Morris, JJ Zhao, CJ Thomas, M Monje Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma Nature, 2017-09-20;549(7673):533-537. 2017-09-20 [PMID: 28959975] (Bioassay, Human)

Bioinformatics

• Gene Symbol: NLGN1
• Uniprot:
  • NP_055747()